In addition to short variants, a patient with ER−/HER2+ breast cancer also exhibited an acquired ERBB2-GRB7 fusion in the follow-up LBx, which retained the extracellular, juxtamembrane, and kinase domains. Here, ERBB2 is linked to breast cancer.